Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Joanne Mortimer, Jack Di Palma, Kendra Schmid, Yining Ye, Mohammad Jahanzeb

ABSTRACT

BACKGROUND: We characterized patterns of occurrence and the impact of neratinib-associated diarrhea in the absence of protocol-directed antidiarrheal prophylaxis or a formal diarrhea management plan using data from Extended Adjuvant Treatment of Breast Cancer with Neratinib (ExteNET). METHODS: ExteNET is a multicenter, double-blind, placebo-controlled, randomized phase III trial involving community-based and academic institutions in 40 countries. Women with HER2-positive early-stage breast cancer with prior standard primary therapy and trastuzumab-based (neo)adjuvant therapy were randomized to neratinib 240 mg/day or placebo for 12 months. Safety, a secondary outcome, was assessed using the National Cancer Institute Common Terminology Criteria version 3.0. Health-related quality of life by diarrhea grade was assessed using Functional Assessment of Cancer Therapy-Breast (FACT-B). RESULTS: Two thousand eight hundred sixteen women (1408 per group) were safety-evaluable. Grade 3 and 4 diarrhea occurred in 561 (39.8%) and 1 (0.1%) patients with neratinib versus 23 (1.6%) and 0 patients with placebo, respectively. In the neratinib group, 28.6% of patients had grade 3 events during month 1 decreasing to ≤ 6% after month 3. The median cumulative duration of grade 3/4 diarrhea with neratinib was 5 days (interquartile range, 2-9). Serious diarrheal events (n = 22, 1.6%) and diarrheal events requiring hospitalization (n = 20, 1.4%) were rare with neratinib. Changes in FACT-B total score by diarrhea grade in the neratinib group did not meet the threshold for clinically important differences. CONCLUSIONS: In the absence of antidiarrheal prophylaxis, neratinib-related diarrhea is short-lived and not associated with complications or long-term sequelae. This suggests that targeted preventive management with antidiarrheal prophylaxis early during neratinib treatment is appropriate. TRIAL REGISTRATION: ClinicalTrials.gov NCT00878709. Registered 9 April 2009. More... »

PAGES

32

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13058-019-1112-5

DOI

http://dx.doi.org/10.1186/s13058-019-1112-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112440321

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30813966


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "City Of Hope National Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "City of Hope Comprehensive Cancer Center, 91010, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mortimer", 
        "givenName": "Joanne", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of South Alabama", 
          "id": "https://www.grid.ac/institutes/grid.267153.4", 
          "name": [
            "University of South Alabama College of Medicine, Mobile, AL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Palma", 
        "givenName": "Jack", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Nebraska Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.266813.8", 
          "name": [
            "College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schmid", 
        "givenName": "Kendra", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Puma Biotechnology Inc., South San Francisco, CA, USA", 
            "Present address: QED Therapeutics, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ye", 
        "givenName": "Yining", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Miami", 
          "id": "https://www.grid.ac/institutes/grid.26790.3a", 
          "name": [
            "Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Deerfield Beach, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jahanzeb", 
        "givenName": "Mohammad", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1634/theoncologist.5-3-250", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000028322"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.25.8707", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007511412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jpainsymman.2007.10.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007787630"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-1978", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010964690"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa064320", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018697395"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00551-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021556818"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2016.0237", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024342372"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-007-9860-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029527984", 
          "https://doi.org/10.1007/s10549-007-9860-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-007-9860-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029527984", 
          "https://doi.org/10.1007/s10549-007-9860-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.canlet.2004.11.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031601781"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70006-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036897855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2013.07.142", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037544865"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-014-2526-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037975934", 
          "https://doi.org/10.1007/s00280-014-2526-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jclinepi.2004.01.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049369635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv129", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050561452"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw695", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059394993"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.09.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.3.974", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083057211"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1703643", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085866538"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30717-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092667029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature25475", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100711838", 
          "https://doi.org/10.1038/nature25475"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature25475", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100711838", 
          "https://doi.org/10.1038/nature25475"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1538-7445.sabcs17-p1-13-11", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101065327"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdz016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111541983"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdz016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111541983"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: We characterized patterns of occurrence and the impact of neratinib-associated diarrhea in the absence of protocol-directed antidiarrheal prophylaxis or a formal diarrhea management plan using data from Extended Adjuvant Treatment of Breast Cancer with Neratinib (ExteNET).\nMETHODS: ExteNET is a multicenter, double-blind, placebo-controlled, randomized phase III trial involving community-based and academic institutions in 40 countries. Women with HER2-positive early-stage breast cancer with prior standard primary therapy and trastuzumab-based (neo)adjuvant therapy were randomized to neratinib 240\u2009mg/day or placebo for 12\u2009months. Safety, a secondary outcome, was assessed using the National Cancer Institute Common Terminology Criteria version 3.0. Health-related quality of life by diarrhea grade was assessed using Functional Assessment of Cancer Therapy-Breast (FACT-B).\nRESULTS: Two thousand eight hundred sixteen women (1408 per group) were safety-evaluable. Grade 3 and 4 diarrhea occurred in 561 (39.8%) and 1 (0.1%) patients with neratinib versus 23 (1.6%) and 0 patients with placebo, respectively. In the neratinib group, 28.6% of patients had grade 3 events during month 1 decreasing to \u2264\u20096% after month 3. The median cumulative duration of grade 3/4 diarrhea with neratinib was 5\u2009days (interquartile range, 2-9). Serious diarrheal events (n\u2009=\u200922, 1.6%) and diarrheal events requiring hospitalization (n\u2009=\u200920, 1.4%) were rare with neratinib. Changes in FACT-B total score by diarrhea grade in the neratinib group did not meet the threshold for clinically important differences.\nCONCLUSIONS: In the absence of antidiarrheal prophylaxis, neratinib-related diarrhea is short-lived and not associated with complications or long-term sequelae. This suggests that targeted preventive management with antidiarrheal prophylaxis early during neratinib treatment is appropriate.\nTRIAL REGISTRATION: ClinicalTrials.gov NCT00878709. Registered 9 April 2009.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13058-019-1112-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1022375", 
        "issn": [
          "1465-5411", 
          "1465-542X"
        ], 
        "name": "Breast Cancer Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "name": "Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial", 
    "pagination": "32", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c96cdb25ec9a2c94b6639e3f8e8f26a88ab9bf12166916bb4a39a2c2b7d67843"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30813966"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100927353"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13058-019-1112-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112440321"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13058-019-1112-5", 
      "https://app.dimensions.ai/details/publication/pub.1112440321"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000358_0000000358/records_127423_00000011.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13058-019-1112-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1112-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1112-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1112-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1112-5'


 

This table displays all metadata directly associated to this object as RDF triples.

173 TRIPLES      21 PREDICATES      51 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13058-019-1112-5 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N9513d99bce6b492486d6963c374f18dc
4 schema:citation sg:pub.10.1007/s00280-014-2526-5
5 sg:pub.10.1007/s10549-007-9860-9
6 sg:pub.10.1038/nature25475
7 https://doi.org/10.1001/jamaoncol.2016.0237
8 https://doi.org/10.1016/j.canlet.2004.11.015
9 https://doi.org/10.1016/j.ejca.2013.07.142
10 https://doi.org/10.1016/j.jclinepi.2004.01.012
11 https://doi.org/10.1016/j.jpainsymman.2007.10.007
12 https://doi.org/10.1016/s1470-2045(14)70006-3
13 https://doi.org/10.1016/s1470-2045(15)00551-3
14 https://doi.org/10.1016/s1470-2045(17)30717-9
15 https://doi.org/10.1056/nejmoa064320
16 https://doi.org/10.1056/nejmoa1703643
17 https://doi.org/10.1093/annonc/mdv129
18 https://doi.org/10.1093/annonc/mdw695
19 https://doi.org/10.1093/annonc/mdz016
20 https://doi.org/10.1158/1078-0432.ccr-08-1978
21 https://doi.org/10.1158/1538-7445.sabcs17-p1-13-11
22 https://doi.org/10.1200/jco.1997.15.3.974
23 https://doi.org/10.1200/jco.2002.09.002
24 https://doi.org/10.1200/jco.2009.25.8707
25 https://doi.org/10.1634/theoncologist.5-3-250
26 schema:datePublished 2019-12
27 schema:datePublishedReg 2019-12-01
28 schema:description BACKGROUND: We characterized patterns of occurrence and the impact of neratinib-associated diarrhea in the absence of protocol-directed antidiarrheal prophylaxis or a formal diarrhea management plan using data from Extended Adjuvant Treatment of Breast Cancer with Neratinib (ExteNET). METHODS: ExteNET is a multicenter, double-blind, placebo-controlled, randomized phase III trial involving community-based and academic institutions in 40 countries. Women with HER2-positive early-stage breast cancer with prior standard primary therapy and trastuzumab-based (neo)adjuvant therapy were randomized to neratinib 240 mg/day or placebo for 12 months. Safety, a secondary outcome, was assessed using the National Cancer Institute Common Terminology Criteria version 3.0. Health-related quality of life by diarrhea grade was assessed using Functional Assessment of Cancer Therapy-Breast (FACT-B). RESULTS: Two thousand eight hundred sixteen women (1408 per group) were safety-evaluable. Grade 3 and 4 diarrhea occurred in 561 (39.8%) and 1 (0.1%) patients with neratinib versus 23 (1.6%) and 0 patients with placebo, respectively. In the neratinib group, 28.6% of patients had grade 3 events during month 1 decreasing to ≤ 6% after month 3. The median cumulative duration of grade 3/4 diarrhea with neratinib was 5 days (interquartile range, 2-9). Serious diarrheal events (n = 22, 1.6%) and diarrheal events requiring hospitalization (n = 20, 1.4%) were rare with neratinib. Changes in FACT-B total score by diarrhea grade in the neratinib group did not meet the threshold for clinically important differences. CONCLUSIONS: In the absence of antidiarrheal prophylaxis, neratinib-related diarrhea is short-lived and not associated with complications or long-term sequelae. This suggests that targeted preventive management with antidiarrheal prophylaxis early during neratinib treatment is appropriate. TRIAL REGISTRATION: ClinicalTrials.gov NCT00878709. Registered 9 April 2009.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree true
32 schema:isPartOf N2601695c425547fc8b9df1f4073c7bbe
33 Nc86ae37bd8a7469cb2cd30cf79e13dd5
34 sg:journal.1022375
35 schema:name Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial
36 schema:pagination 32
37 schema:productId N50e66bd60a65424793481c6a3c688dbe
38 N57a47baf5afc47a39f02bcb445a613d1
39 N8e3b0b13a6074d4d862720a347942529
40 Nc87f3b3b8d5a4c1fb33c536d556aea62
41 Ncd0467920e4d4125b908e17860cffad0
42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112440321
43 https://doi.org/10.1186/s13058-019-1112-5
44 schema:sdDatePublished 2019-04-11T11:35
45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
46 schema:sdPublisher Nd62ad6ceb5384dfb9a63159b42d44d9a
47 schema:url https://link.springer.com/10.1186%2Fs13058-019-1112-5
48 sgo:license sg:explorer/license/
49 sgo:sdDataset articles
50 rdf:type schema:ScholarlyArticle
51 N2601695c425547fc8b9df1f4073c7bbe schema:issueNumber 1
52 rdf:type schema:PublicationIssue
53 N4bde6db232bc45a79e6b3d842ba5bc12 rdf:first Nf89fc1b30cfa4a0ba237b17afcdf0ba3
54 rdf:rest rdf:nil
55 N50e66bd60a65424793481c6a3c688dbe schema:name nlm_unique_id
56 schema:value 100927353
57 rdf:type schema:PropertyValue
58 N57a47baf5afc47a39f02bcb445a613d1 schema:name readcube_id
59 schema:value c96cdb25ec9a2c94b6639e3f8e8f26a88ab9bf12166916bb4a39a2c2b7d67843
60 rdf:type schema:PropertyValue
61 N5e02866a9e5b465494cdedb481543ee7 schema:affiliation https://www.grid.ac/institutes/grid.266813.8
62 schema:familyName Schmid
63 schema:givenName Kendra
64 rdf:type schema:Person
65 N6ad5b00d6d1b416caa0c7214c9c5cf17 schema:affiliation https://www.grid.ac/institutes/grid.267153.4
66 schema:familyName Di Palma
67 schema:givenName Jack
68 rdf:type schema:Person
69 N7081d6dea73649f9a4945af16d987774 rdf:first Nb00a72ab5afa445691bb381125b3fde3
70 rdf:rest N4bde6db232bc45a79e6b3d842ba5bc12
71 N7587cf93b332484ba4e20a0ed95b469f schema:affiliation https://www.grid.ac/institutes/grid.410425.6
72 schema:familyName Mortimer
73 schema:givenName Joanne
74 rdf:type schema:Person
75 N852a96ab1c6b4711ae59c5eecf4e8299 rdf:first N5e02866a9e5b465494cdedb481543ee7
76 rdf:rest N7081d6dea73649f9a4945af16d987774
77 N8e3b0b13a6074d4d862720a347942529 schema:name pubmed_id
78 schema:value 30813966
79 rdf:type schema:PropertyValue
80 N9513d99bce6b492486d6963c374f18dc rdf:first N7587cf93b332484ba4e20a0ed95b469f
81 rdf:rest Ned10fc7927c6445daef03d6976693713
82 Nb00a72ab5afa445691bb381125b3fde3 schema:affiliation Nfce1d56359524ea6983ce5976f7f69f9
83 schema:familyName Ye
84 schema:givenName Yining
85 rdf:type schema:Person
86 Nc86ae37bd8a7469cb2cd30cf79e13dd5 schema:volumeNumber 21
87 rdf:type schema:PublicationVolume
88 Nc87f3b3b8d5a4c1fb33c536d556aea62 schema:name dimensions_id
89 schema:value pub.1112440321
90 rdf:type schema:PropertyValue
91 Ncd0467920e4d4125b908e17860cffad0 schema:name doi
92 schema:value 10.1186/s13058-019-1112-5
93 rdf:type schema:PropertyValue
94 Nd62ad6ceb5384dfb9a63159b42d44d9a schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 Ned10fc7927c6445daef03d6976693713 rdf:first N6ad5b00d6d1b416caa0c7214c9c5cf17
97 rdf:rest N852a96ab1c6b4711ae59c5eecf4e8299
98 Nf89fc1b30cfa4a0ba237b17afcdf0ba3 schema:affiliation https://www.grid.ac/institutes/grid.26790.3a
99 schema:familyName Jahanzeb
100 schema:givenName Mohammad
101 rdf:type schema:Person
102 Nfce1d56359524ea6983ce5976f7f69f9 schema:name Present address: QED Therapeutics, San Francisco, CA, USA
103 Puma Biotechnology Inc., South San Francisco, CA, USA
104 rdf:type schema:Organization
105 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
106 schema:name Medical and Health Sciences
107 rdf:type schema:DefinedTerm
108 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
109 schema:name Oncology and Carcinogenesis
110 rdf:type schema:DefinedTerm
111 sg:journal.1022375 schema:issn 1465-5411
112 1465-542X
113 schema:name Breast Cancer Research
114 rdf:type schema:Periodical
115 sg:pub.10.1007/s00280-014-2526-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037975934
116 https://doi.org/10.1007/s00280-014-2526-5
117 rdf:type schema:CreativeWork
118 sg:pub.10.1007/s10549-007-9860-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029527984
119 https://doi.org/10.1007/s10549-007-9860-9
120 rdf:type schema:CreativeWork
121 sg:pub.10.1038/nature25475 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100711838
122 https://doi.org/10.1038/nature25475
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1001/jamaoncol.2016.0237 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024342372
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1016/j.canlet.2004.11.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031601781
127 rdf:type schema:CreativeWork
128 https://doi.org/10.1016/j.ejca.2013.07.142 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037544865
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1016/j.jclinepi.2004.01.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049369635
131 rdf:type schema:CreativeWork
132 https://doi.org/10.1016/j.jpainsymman.2007.10.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007787630
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1016/s1470-2045(14)70006-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036897855
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1016/s1470-2045(15)00551-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021556818
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1016/s1470-2045(17)30717-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092667029
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1056/nejmoa064320 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018697395
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1056/nejmoa1703643 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085866538
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1093/annonc/mdv129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050561452
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1093/annonc/mdw695 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059394993
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1093/annonc/mdz016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111541983
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1158/1078-0432.ccr-08-1978 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010964690
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1158/1538-7445.sabcs17-p1-13-11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101065327
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1200/jco.1997.15.3.974 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083057211
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1200/jco.2002.09.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203115
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1200/jco.2009.25.8707 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007511412
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1634/theoncologist.5-3-250 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000028322
161 rdf:type schema:CreativeWork
162 https://www.grid.ac/institutes/grid.266813.8 schema:alternateName University of Nebraska Medical Center
163 schema:name College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA
164 rdf:type schema:Organization
165 https://www.grid.ac/institutes/grid.267153.4 schema:alternateName University of South Alabama
166 schema:name University of South Alabama College of Medicine, Mobile, AL, USA
167 rdf:type schema:Organization
168 https://www.grid.ac/institutes/grid.26790.3a schema:alternateName University of Miami
169 schema:name Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Deerfield Beach, FL, USA
170 rdf:type schema:Organization
171 https://www.grid.ac/institutes/grid.410425.6 schema:alternateName City Of Hope National Medical Center
172 schema:name City of Hope Comprehensive Cancer Center, 91010, Duarte, CA, USA
173 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...